Twice per year the NCL accepts the most promising cancer nanomedicine candidates into its Assay Cascade characterization and testing program. Nanomedicines accepted into the program will undergo a rigorous evaluation that may include sterility and endotoxin testing, physicochemical characterization, in vitro hemato- and immunotoxicity, and in vivo studies to evaluate safety, efficacy and pharmacokinetics. The […]
By Eric Hamilton In the treatment of cancer, chemotherapy is a cleaver, not a scalpel. By attacking rapidly dividing cells, chemotherapy effectively fights tumors, but it also ravages healthy cells in the gut, bone marrow, the scalp and other organs, leading to severe side effects. These toxic chemicals save lives, but at a great cost […]
School of Pharmacy faculty entrepreneurs bring technology from the lab to the marketplace By Katie Ginder-Vogel It’s not easy starting a new company, and it’s even more demanding to be an entrepreneur while also working full time as a professor at one of the top pharmacy schools in the country. Running a startup and a […]
Co-D Therapeutics, a University of Wisconsin–Madison spinoff, is developing a three-drug cocktail to battle a wide range of cancers. The first target for Co-D is angiosarcoma, a rare and lethal cancer that arises from blood vessels. The company’s submicroscopic package contains paclitaxel, a standard cancer drug, combined with two other drugs designed to reduce the […]
Co-D Therapeutics, Inc., a pre-clinical stage pharmaceutical company developing agents for the treatment of cancer, announced that the U.S. Food and Drug Administration (FDA) has granted Co-D’s request for orphan drug designation of Triolimus for the treatment of the highly lethal malignancy, angiosarcoma. “We are pleased that Triolimus has been designated an orphan drug for […]
Madison-based Co-D Therapeutics Inc. said Tuesday the U.S. Food and Drug Administration has granted orphan drug status for a drug it is developing for the treatment of a rare cancer of the inner lining of blood vessels. The Orphan Drug Act provides economic incentives to encourage the development of drugs for diseases affecting fewer than […]
Driven by the knowledge that their unique combination of skills may save lives, pharmaceutical researcher Glen Kwon and radiation oncologist Dr. Kevin Kozak hope to make a difference. The two University of Wisconsin–Madison faculty members are developing a new drug combination and delivery method that promises to attack hard-to-treat solid tumors.